TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent thrombosis in the leg veins, pulmonary arteries and placental vessels, thereby reducing the risk of deep vein thrombosis, pulmonary embolism, intrauterine growth restriction (IUGR), preeclampsia, miscarriage and stillbirth?
| Condition | Intervention | Phase |
|---|---|---|
|
Pregnancy Thrombophilia Pregnancy Complications |
Drug: dalteparin sodium |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women. |
- The primary objective of the study is to identify if LMWH prophylaxis in thrombophilic pregnant women results in a greater than 33% relative risk reduction in the composite outcome measure (VTE, pre-eclampsia, IUGR and fetal loss) [ Time Frame: 6 weeks post-partum ] [ Designated as safety issue: No ]
- Identify if prophylactic LMWH will reduce rates of PIH, preterm labor and abruptio placenta in pregnant thrombophilic women compared to control [ Time Frame: 6 weeks post-partum ] [ Designated as safety issue: No ]
- Determine the safety of LMWH use in pregnancy (Specifically rates of bleeding, thrombocytopenia and fractures) [ Time Frame: 6 weeks post-partum ] [ Designated as safety issue: Yes ]
- Identify whether prolonged use of LMWH in pregnancy results in decreased BMD compared to control [ Time Frame: 6 weeks post-partum ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 284 |
| Study Start Date: | July 2000 |
| Estimated Study Completion Date: | March 2014 |
| Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Control
Subjects randomized to control will receive identical obstetrical care and follow-up, but not antenatal dalteparin. Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum |
|
|
Active Comparator: dalteparin sodium
Subjects randomized to the treatment group will receive daily injections of dalteparin during the antenatal period. They will be taught how to self-administer sub-cutaneous injections of dalteparin 5000 IU once daily (o.d.) until gestational age 20, then twice daily (bid) until 37 weeks gestation or onset of labour. Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum |
Drug: dalteparin sodium
Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then; dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician) Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum Other Name: Fragmin
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
One or more of the following:
- Previous preeclampsia
- Previous unexplained intra-uterine growth restriction
Previous recurrent miscarriage:
- three(3) or more unexplained miscarriage at less than 10 weeks gestation;
- two (2) or more unexplained fetal loss between 10 and 16 weeks gestation;
- one (1) or more unexplained fetal loss at or greater than 16 weeks gestation
- Previous abruptio placenta
Previous personal history of VTE:
- Previous documented secondary proximal VTE,
- Previous documented calf-vein thrombosis (idiopathic or secondary),
- Previous superficial phlebitis
- First degree relative with symptomatic thrombophilia
- Pregnancy - > 4weeks gestation and < 20 weeks gestation
- Thrombophilia:
Two abnormal tests, and no normal tests
- 3.1 Protein S
- 3.2 Protein C
- 3.3 Antithrombin
Two positive tests
- 3.4 Anticardiolipin IgM (>30 U/ml)
- 3.5 Anticardiolipin IgG (>30 U/ml)
- 3.6 Anti-b2 glycoprotein IgG (>20 U/ml)
- 3.7 Anti-b2 glycoprotein IgM (>20 U/ml)
- 3.8 Lupus anticoagulant
One positive test
- 3.9 Factor V Leiden (heterozygous or homozygous)
- 3.10Prothrombin gene defect (heterozygous or homozygous)
Exclusion Criteria:
- Less than 4 weeks gestation or greater than 20 weeks gestation
- No confirmed thrombophilia
Contraindication to heparin therapy
- History of heparin induced thrombocytopenia
- Platelet count less than 100,000 109/L
- History of osteoporosis or steroid use
- Actively bleeding
- Documented peptic ulcer within 6 weeks
- Heparin, bisulfite or fish allergy
- Severe hypertension (SBP >200mmhg and/or DBP >120mmHg)
- Serum creatinine greater than 80 umol/L (1.3mg/dl) and an abnormal 24 hour urine creatine clearance (<30ml/min)
- Severe hepatic failure (INR >1.8)
- Geographic inaccessibility
Need for anticoagulants, discretion of the investigator such as but not limited to:
- Recurrent fetal loss and phospholipid antibody syndrome
- Prior idiopathic proximal VTE:
- History of idiopathic DVT or PE treated with anticoagulants (> 1 month of heparin or warfarin) or IVC interruption;
- Idiopathic is a VTE occurring outside all of the following periods: antepartum, postpartum, oral contraceptive use, surgery, immobilization, cast, and malignancy
- Mechanical heart valve
- Legal lower age limitations (country specific)
- Prior participation in TIPPS
- Unable/unwilling to provide informed consent
Contacts and Locations| United States, Missouri | |
| Saint Louis University | |
| Saint Louis, Missouri, United States, 63117 | |
| United States, Utah | |
| University of Utah Health Sciences Centre | |
| Salt Lake City, Utah, United States, 84132 | |
| Canada, Alberta | |
| Royal Alexandra Hospital | |
| Edmonton, Alberta, Canada | |
| Canada, Nova Scotia | |
| QEII Health Sciences Centre | |
| Halifax, Nova Scotia, Canada | |
| Canada, Ontario | |
| Hamilton Health Sciences Centre | |
| Hamilton, Ontario, Canada | |
| The Ottawa Hospital, Civic Campus | |
| Ottawa, Ontario, Canada | |
| Women's College Health Sciences Centre | |
| Toronto, Ontario, Canada | |
| Mount Sinai Hospital | |
| Toronto, Ontario, Canada | |
| Canada, Quebec | |
| SMBD Jewish General Hospital | |
| Montreal, Quebec, Canada | |
| St Mary's Hospital Centre | |
| Montreal, Quebec, Canada | |
| Canada, Saskatchewan | |
| Royal University Hospital | |
| Saskatoon, Saskatchewan, Canada | |
| Canada | |
| CHA, Hopital Enfant Jesus | |
| Quebec, Canada | |
| Principal Investigator: | Marc A Rodger, MD | Ottawa Hospital Research Institute, Ottawa, Canada |
| Principal Investigator: | William Hague, MD | Women's and Children's Hospital, Adelaide, Australia |
More Information
Additional Information:
No publications provided by Ottawa Hospital Research Institute
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Ottawa Hospital Research Institute |
| ClinicalTrials.gov Identifier: | NCT00967382 History of Changes |
| Other Study ID Numbers: | 1999210-01H, IND 72,350, ISRCTN 87441504, CIHR 200602MCT-157533-RFA, Trial number 2004/244, 2007-000284-21 |
| Study First Received: | May 29, 2009 |
| Last Updated: | April 22, 2013 |
| Health Authority: | United States: Food and Drug Administration Australia: Department of Health and Ageing Therapeutic Goods Administration Canada: Health Canada |
Keywords provided by Ottawa Hospital Research Institute:
|
Pregnancy Thrombophilia High-risk pregnancy LMWH prophylaxis Placenta mediated pregnancy complications |
Additional relevant MeSH terms:
|
Pregnancy Complications Thrombophilia Hematologic Diseases Heparin, Low-Molecular-Weight Dalteparin Anticoagulants Hematologic Agents |
Therapeutic Uses Pharmacologic Actions Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 23, 2013